Nomogram

ZEISS Sets Stage for Future of Ophthalmic Surgery and 3D Visualization at ASCRS 2024

Retrieved on: 
Thursday, March 28, 2024
Glaucoma, Nomogram, ASCRS, Patient, Eye, SCI, Astigmatism, Surgeon, Workflow, 3D, Cataract, HDR, LVC, Biostatistics, Health, Food, 2D, Bed, Digital, Near-sightedness, Sharp HealthCare, FDA, Movement, LASIK, Temperature, SMILE, Refractive surgery, RGB, News, Silicon, Workplace, Society, Retina, Human, Telescopic sight

Product News: ZEISS announces enhanced visualization capabilities with the new ZEISS ARTEVO 850 3D heads-up ophthalmic microscope.

Key Points: 
  • Product News: ZEISS announces enhanced visualization capabilities with the new ZEISS ARTEVO 850 3D heads-up ophthalmic microscope.
  • Spatial Computing Innovation: ZEISS will demonstrate a digital application for experiencing 3D videos and more on the Apple Vision Pro.
  • ZEISS is extending its workflow offerings with new surgical and visualization technologies at ASCRS.
  • At ASCRS, surgeons are invited to join the ZEISS SMILE Speed Competition in lenticule extraction with the new ZEISS VISUMAX 800.

ZEISS Sets Stage for Future of Ophthalmic Surgery and 3D Visualization at ASCRS 2024

Retrieved on: 
Thursday, March 28, 2024
Glaucoma, Nomogram, ASCRS, Patient, Eye, SCI, Astigmatism, Surgeon, Workflow, 3D, Cataract, HDR, LVC, Biostatistics, Health, Food, 2D, Bed, Digital, Near-sightedness, Sharp HealthCare, FDA, Movement, LASIK, Temperature, SMILE, Refractive surgery, RGB, News, Silicon, Workplace, Society, Retina, Human, Telescopic sight

Product News: ZEISS announces enhanced visualization capabilities with the new ZEISS ARTEVO 850 3D heads-up ophthalmic microscope.

Key Points: 
  • Product News: ZEISS announces enhanced visualization capabilities with the new ZEISS ARTEVO 850 3D heads-up ophthalmic microscope.
  • Spatial Computing Innovation: ZEISS will demonstrate a digital application for experiencing 3D videos and more on the Apple Vision Pro.
  • ZEISS is extending its workflow offerings with new surgical and visualization technologies at ASCRS.
  • At ASCRS, surgeons are invited to join the ZEISS SMILE Speed Competition in lenticule extraction with the new ZEISS VISUMAX 800.

EQS-News: U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS

Retrieved on: 
Saturday, January 13, 2024
Digital technology, Bed, Patient, Nomogram, MD, Astigmatism, Near-sightedness, Quality of life, SMILE, Food, Hertz, FDA, Surgeon

The updated ZEISS femtosecond laser provides U.S. refractive surgeons with faster treatment, greater flexibility, and significant workflow enhancements.

Key Points: 
  • The updated ZEISS femtosecond laser provides U.S. refractive surgeons with faster treatment, greater flexibility, and significant workflow enhancements.
  • ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism.
  • With these workflow enhancements along with greater flexibility and faster treatment, the VISUMAX® 800 with SMILE® pro software from ZEISS offers substantial market opportunities for U.S. surgeons.
  • For more information about the VISUMAX® 800 with SMILE® pro software from ZEISS, visit www.zeiss.com/us/visumax-800 .

U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS

Retrieved on: 
Thursday, January 11, 2024
Digital technology, Bed, Patient, Nomogram, MD, Astigmatism, Near-sightedness, Quality of life, SMILE, Food, Hertz, FDA, Surgeon

DUBLIN, Calif. and JENA, Germany, Jan. 11, 2024 /PRNewswire/ -- Carl Zeiss Meditec AG -- ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism. The latest generation of femtosecond lasers from ZEISS enters the U.S. market at a time when more than 8 million eyes have been treated with SMILE worldwide, reflecting the technology's broad global momentum driven by strong adoption in Asia and Europe.

Key Points: 
  • DUBLIN, Calif. and JENA, Germany, Jan. 11, 2024 /PRNewswire/ -- Carl Zeiss Meditec AG -- ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism.
  • The VISUMAX® 800 with SMILE® pro software from ZEISS enables faster treatment, creating the lenticule in less than 10 seconds thanks to a faster laser pulse repetition rate of 2 MHz.
  • With these workflow enhancements along with greater flexibility and faster treatment, the VISUMAX® 800 with SMILE® pro software from ZEISS offers substantial market opportunities for U.S. surgeons.
  • For more information about the VISUMAX® 800 with SMILE® pro software from ZEISS, visit www.zeiss.com/us/visumax-800 .

U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS

Retrieved on: 
Thursday, January 11, 2024
Digital technology, Bed, Patient, Nomogram, MD, Astigmatism, Near-sightedness, Quality of life, SMILE, Food, Hertz, FDA, Surgeon

DUBLIN, Calif. and JENA, Germany, Jan. 11, 2024 /PRNewswire/ -- Carl Zeiss Meditec AG -- ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism. The latest generation of femtosecond lasers from ZEISS enters the U.S. market at a time when more than 8 million eyes have been treated with SMILE worldwide, reflecting the technology's broad global momentum driven by strong adoption in Asia and Europe.

Key Points: 
  • DUBLIN, Calif. and JENA, Germany, Jan. 11, 2024 /PRNewswire/ -- Carl Zeiss Meditec AG -- ZEISS Medical Technology announced today that the U.S. Food and Drug Administration (FDA) has approved the VISUMAX® 800 with SMILE® pro software from ZEISS for surgically treating nearsightedness, with or without astigmatism.
  • The VISUMAX® 800 with SMILE® pro software from ZEISS enables faster treatment, creating the lenticule in less than 10 seconds thanks to a faster laser pulse repetition rate of 2 MHz.
  • With these workflow enhancements along with greater flexibility and faster treatment, the VISUMAX® 800 with SMILE® pro software from ZEISS offers substantial market opportunities for U.S. surgeons.
  • For more information about the VISUMAX® 800 with SMILE® pro software from ZEISS, visit www.zeiss.com/us/visumax-800 .

Castle Biosciences Reports First Quarter 2023 Results

Retrieved on: 
Wednesday, May 3, 2023
Research, Genetics, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Gastroenterology, GEP, Archive, Literature, Dermatology, EBITDA, Guideline, CM, Nomogram, Castle, BWH, Trial of the century, Lymph node, News, National Society, Pharmaceutical industry, Video game, Lithium, Vaccine, Cryptocurrency, Brigham

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2023.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2023.
  • Delivered 14,916 total test reports in the first quarter of 2023, an increase of 73% compared to 8,627 in the same period of 2022:
    DecisionDx-Melanoma test reports delivered in the quarter were 7,583, compared to 6,023 in the first quarter of 2022, an increase of 26%.
  • MyPath® Melanoma test reports delivered in the quarter were 980, compared to 950 MyPath-Melanoma and DiffDx-Melanoma aggregate test reports in the first quarter of 2022, an increase of 3%.
  • Castle Biosciences will hold a conference call on Wednesday, May 3, 2023, at 4:30 p.m. Eastern time to discuss its first quarter 2023 results and provide a corporate update.

Recommendations by Expert Consensus Panel Relating to Risk-Stratification Tests and Tools for Use in Cutaneous Melanoma Have Been Adopted as an Official Policy Recommendation of the National Society for Cutaneous Medicine

Retrieved on: 
Wednesday, March 8, 2023
Biotechnology, Health, Oncology, Other Health, Journal of Cutaneous Medicine and Surgery, SORT, Metastasis, Dermatology, Nomogram, GEP, Death, Sentinel lymph node, Recurrence, Patient, Literature, Risk, Neoplasm, Policy, Melanoma, SLN, National Society, Prognosis, Medical device, Medical imaging, SKIN

The report provides usage guidelines and a framework for clinicians to integrate GEP testing into their CM patient management.

Key Points: 
  • The report provides usage guidelines and a framework for clinicians to integrate GEP testing into their CM patient management.
  • Additionally, the consensus report endorses Castle’s DecisionDx®-Melanoma GEP risk stratification test as offering more utility than other existing CM GEP assays or nomograms, supported by extensive, evidence-driven data in current literature.
  • The panel reviewed 32 studies published between 2019 through 2022 assessing the use of GEP testing in CM prognosis.
  • Each of the recommendations was given a strength “A,” “B,” or “C” according to Strength of Recommendation Taxonomy (SORT) criteria.

PreludeDx™ Presents New Data at the 40th Annual Miami Breast Cancer Conference Identifying Which Patients with DCIS May Be Undertreated Based on Clinicopathologic Factors Alone

Retrieved on: 
Thursday, March 2, 2023
Patient, CP, Additive effect, Active surveillance of low-risk papillary thyroid microcarcinoma, Washington University School of Medicine, Woman, HT, DCIS, MBCC, FACS, Therapy, Fontainebleau Miami Beach, Conference, Alvin J. Siteman Cancer Center, Breast, Clinical research, MSKCC, Cleveland Clinic, Ductal carcinoma, Memorial Sloan Kettering Cancer Center, RT, Medicine, Poster, IBR, Comparative oncology, Nomogram, BCS, Medical imaging, Nursing, Pharmaceutical industry, Radiation therapy, MD

LAGUNA HILLS, Calif., March 2, 2023 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced it will be presenting data comparing risk stratification and radiation benefit (RT) for patients with ductal carcinoma in situ (DCIS) using DCISionRT™ with a clinicopathologic (CP) model similar to the Memorial Sloan Kettering Cancer Center (MSKCC) DCIS nomogram at the 40th Annual Miami Breast Cancer Conference (MBCC), being held on March 2 – 5, 2023 at the Fontainebleau Miami Beach.

Key Points: 
  • The study included 926 DCIS patients from four cohorts who were treated with breast conserving surgery (BCS) or BCS + radiation therapy (RT).
  • The study compared MSKCC DCIS nomogram-like model with the DCISionRT 7-gene biosignature.
  • "DCISionRT provides us the clinical evidence to identify which DCIS patients, despite having low-risk clinicopathologic features, can actually benefit from RT and which patients may safely omit RT."
  • The registry includes females 26 and older who are diagnosed with DCIS and are candidates for BCS and eligible for RT.